Compare VanEck Rare Earth/Strategic Metals (REMX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs GeneDx Holdings Corp — how do they compare? VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and GeneDx Holdings Corp for 19 Days on average.
| REMX | WGS | |
|---|---|---|
Market Cap | $1.75B | $2.02B |
Volume | 930,523 | 734,640 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $167.51 |
52-Week Low | $60.58 | $34.51 |
Typical Hold Time | 50 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.58, down 2.1% with a bearish technical outlook. The ETF shows high volatility and faces pressure from rare earth market dynamics. Recent news highlights geopolitical tensions around critical minerals and China's export controls, while institutional interest includes Bank of America increasing its stake by 72.1% in Q2 2026 (SEC filing, August 2026).
Outlook remains cautious due to sector volatility and China dependency risks. Investment appeal lies in strategic positioning for supply chain independence, but high turnover and exposure fluctuations warrant careful risk assessment. Key catalysts include U.S. policy developments and rare earth supply chain expansions.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
